ClinicalTrials.gg
CompletedNCT00791479Updated Dec 10, 2014Results posted

Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes

A Phase 2 interventional study of LY2189265 and Lifestyle Measures and Placebo solution and Lifestyle Measures in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 46 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-12-10.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
167
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
26th of 54
167 · median 159
Started
2008
with 2 others
Phase 2
5 of 54
none open now
Registered
3rd of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 26th largest by enrollment, is one of 3 that started in 2008, is one of 5 in phase 2, and was the 3rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is a study to demonstrate that different doses of once-weekly LY2189265 injected subcutaneously will have dose proportional effect on hemoglobin A1c (HbA1c) at 12 weeks in participants with type 2 diabetes mellitus.

Read the detailed description

Participants in the trial will be randomized to one of the LY2189265 doses (4 doses are planned, range 0.1-1.5 milligram [mg]) or placebo. The main purpose is to assess dose-dependent effect of this new compound on blood glucose over a period of 12 weeks. Therefore, glycosylated hemoglobin (HbA1c) is chosen as the primary efficacy measure. Several other attributes of glycemic control and endocrine function of pancreas will be assessed as secondary objectives. These secondary objectives will be used to compare the effect of the experimental compound and placebo. Since LY2189265 is in early phase of development, comprehensive safety assessment is planned to learn more about possible side-effects and to establish benefit/risk profile of individual doses of the drug. The trial is organized in four phases: screening, lead-in period to establish baseline status of participants in each group, treatment period during which participants will be randomized into 1 of 5 groups (4 will receive one of the LY2189265 doses, 1 group will receive placebo), and safety follow up. Maximum of 9 study visits are planned. Study drug (LY2189265 or placebo) will be administered once weekly via subcutaneous (SC) injections. Rescue intervention was allowed after randomization for those participants whose hyperglycemia reached pre-defined unacceptable high values. Participants on rescue therapy remained in the study and continued to receive study drug. Participants who received rescue therapy were included in the analysis population, but only measurements obtained prior to the beginning of rescue therapy were included in specified efficacy analyses.

A 3-mg LY2189265 dose was discontinued and replaced with the 1.5 mg dose based on dose finding Study H9X-MC-GBCF; NCT00734474. Except where noted, data summaries from the 3 discontinued 3-mg LY2189265 participants (n=3) are not included due to the small number of participants and the short treatment duration.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Diabetes, type 2 diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diabetes mellitus, type 2
  • Treatment regimens: diet and exercise only or are taking metformin as monotherapy and are willing to discontinue this medication
  • Have completed at least 8 weeks of prior to randomization (if on metformin therapy at screening)
  • Have a qualifying glycosylated () value, as determined by the central laboratory: at screening (for diet and exercise only ≥7.0% to ≤9.5%; for metformin monotherapy >6.5% to ≤9.0%) and at time of randomization for all participants ≥6.5% to ≤9.5%
  • Females of must test negative for pregnancy and agree to use a reliable method
  • Have a (BMI) between 23 and 40 kilograms/meter squared (kg/m\^2), inclusive, for participants who are native to, and reside in, South and/or East Asia; all other participants must have a BMI between 25 and 40 kg/m\^2, inclusive.
  • Stable weight for 3 months prior to screening

Exclusion criteria

Exclusion Criteria:

  • Diabetes mellitus, type 1
  • Taking any glucose-lowering oral agents other than metformin within 3 months prior to screening
  • Use of glucagon-like peptide-1 (GLP-1) analog (for example, exenatide) within 6 months prior to screening or being treated within insulin (with the exception of short-term management of acute conditions that occurred more than 3 months immediately prior to screening)
  • Use of medications (prescription or over-the counter) to promote weight loss
  • Chronic (>2 weeks) use of systemic therapy
  • Gastric emptying abnormality, history of bariatric surgery or chronic use of drugs that affect gastrointestinal motility
  • Use of central nervous system (CNS) stimulant (for example, Ritalin-sustained release [SR])
  • Cardiovascular event within 6 months prior to screening
  • Poorly controlled hypertension (determined by a mean seated systolic blood pressure (BP) ≥160 millimeters of mercury (mmHg) or mean seated diastolic BP ≥95 mmHg at screening or randomization)
  • (ECG) reading considered outside the normal limits by the investigator and relevant for interpretation or indicating cardiac disease
  • Liver disease, hepatitis, chronic hepatitis, or levels >3.0 times
  • Clinical signs or symptoms of pancreatitis or history of chronic or acute pancreatitis at time of screening
  • Amylase ≥3 times the upper limit of normal and/or lipase ≥2 times upper limit of normal which are determined by central labs at the time of screening
  • Serum creatinine ≥1.5 milligrams per deciliter (mg/dL) for men or ≥1.4 mg/dL for women or a \<60 milliliter (mL)/minute which are determined by central labs at the time of screening
  • Uncontrolled diabetes (defined as 2 or more episode of hyperosmolar state requiring hospitalization in the 6 months prior to screening)
  • Significant active, uncontrolled endocrine or abnormality
  • History of a transplanted organ (corneal transplants are allowed)
  • Active or untreated (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years
  • Have any other condition, in the opinion of the investigator, that may preclude the participant from following or completing the protocol
  • Investigator site personnel directly affiliated with this study and/or their immediate families (spouse, parent, child, or sibling, whether biological or legally adopted)
  • Sponsor employees
  • Received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry
  • Participated in an interventional medical, surgical, or pharmaceutical study within 30 days prior to entry into the study
  • Have previously completed or withdrawn from this study after providing
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
167 participants (actual)

Study arms

  • Experimental
    0.1 milligram (mg) LY2189265

    LY2189265: 0.1 milligram (mg), subcutaneous (SC), once weekly (QW)

    Drug: LY2189265 and Lifestyle Measures

  • Experimental
    0.5 milligram (mg) LY2189265

    LY2189265: 0.5 milligram (mg), subcutaneous (SC), once weekly (QW)

    Drug: LY2189265 and Lifestyle Measures

  • Experimental
    1.0 milligram (mg) LY2189265

    LY2189265: 1.0 milligram (mg), subcutaneous (SC), once weekly (QW)

    Drug: LY2189265 and Lifestyle Measures

  • Experimental
    1.5 milligram (mg) LY2189265

    LY2189265: 1.5 milligram (mg), subcutaneous (SC), once weekly (QW)

    Drug: LY2189265 and Lifestyle Measures

  • Placebo comparator
    Placebo

    Placebo: subcutaneous (SC) once weekly (QW)

    Drug: Placebo solution and Lifestyle Measures

Interventions

  • DrugLY2189265 and Lifestyle Measures

    Drug page: Dulaglutide

    Subcutaneous injection once-weekly for up to 12 weeks

    Also known as: Dulaglutide

  • DrugPlacebo solution and Lifestyle Measures

    Subcutaneous injection once-weekly for up to 12 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c)

    Least Squares (LS) means of change from baseline for glycosylated hemoglobin (HbA1c) were calculated using mixed model repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline HbA1c as covariate.

    Time frame: Baseline, 12 weeks

Secondary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c)

    Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline glycosylated hemoglobin (HbA1c) as covariate.

    Time frame: Baseline, 4 weeks, 8 weeks

  2. Change From Baseline in Fasting Blood Glucose

    Fasting blood glucose is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline fasting glucose as covariate.

    Time frame: Baseline, 12 weeks

  3. Percentage of Participants Who Achieve Glycosylated Hemoglobin (HbA1c) <7% or ≤6.5%

    Percentages of participants who achieved glycosylated hemoglobin (HbA1c) levels of \<7.0% or ≤6.5% were compared across treatment arms using the Cochran-Armitage trend test.

    Time frame: 12 weeks

  4. Change From Baseline in Daily Mean Blood Glucose Values From the 7-point Self Monitored Blood Glucose (SMBG) Profiles

    Change from baseline in mean daily blood glucose values were measured with a 7-point self-monitored blood glucose (SMBG) profile over a 24-hour period in the 7-day period prior to each visit. The 7-point SMBG profile consisted of preprandial blood glucose measures before the morning, midday, and evening meals; blood glucose measures 2 hours after the start of the morning, midday, and evening meals; and the fasting blood glucose obtained the following morning. Mean at 12 weeks was assessed in all treatment groups. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and as covariate.

    Time frame: Baseline, 12 weeks

  5. Change From Baseline in Beta-cell Function (HOMA2-%B)

    Change from baseline in beta (β)-cell function (HOMA2-%B) was assessed by using the homeostatic model assessment (HOMA) to quantify β-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta cell function (%B), as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. Least Squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline HOMA2-%B as covariate.

    Time frame: Baseline, 12 weeks

  6. Change From Baseline in Insulin Sensitivity (HOMA2-%S)

    Change from baseline in insulin sensitivity (HOMA2-%S) was assessed by using the homeostatic model assessment (HOMA) to quantify insulin sensitivity. HOMA2-%S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state insulin sensitivity (%S), as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. Least Squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline HOMA2-%S as covariate.

    Time frame: Baseline, 12 weeks

  7. Change From Baseline in Electrocardiograms (ECGs) - Fridericia-corrected QT (QTcF) and PR Interval

    The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. The PR segment begins at the endpoint of the P wave and ends at the onset of the QRS complex. Least Squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline measurement as covariate.

    Time frame: Baseline, 12 weeks

  8. Change From Baseline in Electrocardiograms (ECGs) - Heart Rate

    Least Squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline measurement as covariate.

    Time frame: Baseline, 12 weeks

  9. Change From Baseline in Pulse Rate

    Sitting pulse rate was measured. Least Squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline measurement as covariate.

    Time frame: Baseline, 12 weeks

  10. Change From Baseline in Blood Pressure (BP)

    Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change were calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline measurement as covariate.

    Time frame: Baseline, 12 weeks

  11. Number of Participants With Self-reported Hypoglycemic Events

    Hypoglycemic events were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined an event during which typical symptoms of hypoglycemia were accompanied by a blood glucose level of ≤3.9 millimoles per liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured blood glucose of ≤3.9 mmol/L), or nocturnal (defined as any hypoglycemic event that occurred between bedtime and breakfast with a measured blood glucose of ≤3.9 mmol/L). Participant reports of hypoglycemic events were collected at the beginning of each visit starting at Baseline. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 12 weeks

  12. Rate of Self-reported Hypoglycemic Events

    Hypoglycemic events (HE) were classified as severe (defined as events requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined an event during which typical symptoms of hypoglycemia were accompanied by a blood glucose level of ≤3.9 millimoles per liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured blood glucose of ≤3.9 mmol/L), or nocturnal (defined as any HE that occurred between bedtime and breakfast with a measured blood glucose of ≤3.9 mmol/L). Participant reports of HE were collected at the beginning of each visit starting at Baseline and the annualized rate was reported. Least Squares (LS) means rates were adjusted for pre-study therapy, country, and baseline body mass index. A summary of AEs regardless of causality is located in the Reported AEs module. Some model-adjusted LS means are less than 0 and may be interpreted as very low rates.

    Time frame: Baseline through 12 weeks

  13. Treatment Emergent Adverse Events

    A treatment emergent adverse event is any untoward medical occurrence that either occurs or worsens at any time after the first injection of study drug following randomization and which does not necessarily have to have a causal relationship. The number of participants with one or more treatment emergent adverse event was reported. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 12 weeks

  14. Change From Baseline in Body Weight

    Least Squares (LS) means was calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline measurement as covariate.

    Time frame: Baseline, 12 weeks

  15. Antibody Production and Effects to LY2189265

    LY2189265 anti-drug antibodies (ADA) were assessed at baseline, 4 and 12 weeks, and at the safety follow-up visit 4 weeks after study drug discontinuation (16 weeks). The number of participants with initial postbaseline detection of treatment emergent (defined as a 4-fold increase in the ADA titer from baseline) LY2189265 ADA at each time point were summarized.

    Time frame: Baseline, 4 weeks, 12 weeks, 16 weeks

  16. Collection and Evaluation of Plasma Levels (Pharmacokinetics [PK]) of LY2189265

    The population mean estimates and standard deviations were calculated for pharmacokinetic parameters (area under the concentration time curve (AUC) from zero to 168 hours). Evaluable PK concentrations from the 4 week, 8 week, and 12 week timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.

    Time frame: 4 weeks, 8 weeks, 12 weeks

07

Results

Posted Dec 10, 2014

Participant flow

Participant flow — Overall Study
Milestone0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY21892653.0 Milligrams (mg) LY2189265Placebo
Started35343429332
Received at least one dose of study drug35343429332
Completed33313425029
Not completed230433
Withdrew: Dose discontinued per sponsor decision000030
Withdrew: Adverse event010201
Withdrew: Lost to follow-up010001
Withdrew: Protocol violation210100
Withdrew: Withdrawal by subject000101

Outcome measures

PrimaryChange From Baseline in Glycosylated Hemoglobin (HbA1c)

Least Squares (LS) means of change from baseline for glycosylated hemoglobin (HbA1c) were calculated using mixed model repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline HbA1c as covariate.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change From Baseline in Glycosylated Hemoglobin (HbA1c)
percentage of glycosylated hemoglobin0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY2189265Placebo
Change From Baseline in Glycosylated Hemoglobin (HbA1c)-0.37 ± 0.11-0.89 ± 0.12-1.03 ± 0.11-1.04 ± 0.130.01 ± 0.13
Statistical analysis
  • 0.1 Milligrams (mg) LY2189265 vs 0.5 Milligrams (mg) LY2189265 vs 1.0 Milligrams (mg) LY2189265 vs 1.5 Milligrams (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (A priori threshold for statistical significance was p\<0.05.)
  • 0.1 Milligrams (mg) LY2189265 vs 0.5 Milligrams (mg) LY2189265 vs 1.0 Milligrams (mg) LY2189265 vs 1.5 Milligrams (mg) LY2189265 · Mixed Models Analysis · p = <0.001 (A priori threshold for statistical significance was p\<0.05.)
  • 0.1 Milligrams (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.069 (An adjustment for multiplicity was performed when comparing the individual doses to placebo using a Dunnett's test.) · Mean difference (final values): -0.37
  • 0.5 Milligrams (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (An adjustment for multiplicity was performed when comparing the individual doses to placebo using a Dunnett's test.) · Mean difference (final values): -0.89
  • 1.0 Milligrams (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (An adjustment for multiplicity was performed when comparing the individual doses to placebo using a Dunnett's test.) · Mean difference (final values): -1.04
  • 1.5 Milligrams (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (An adjustment for multiplicity was performed when comparing the individual doses to placebo using a Dunnett's test.) · Mean difference (final values): -1.04
SecondaryChange From Baseline in Glycosylated Hemoglobin (HbA1c)

Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline glycosylated hemoglobin (HbA1c) as covariate.

Time frame:
Baseline, 4 weeks, 8 weeks
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change From Baseline in Glycosylated Hemoglobin (HbA1c)
percentage of glycosylated hemoglobin0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY2189265Placebo
Week 4 (n=35, n=34, n=34, n=25, n=29)-0.28 ± 0.09-0.51 ± 0.09-0.46 ± 0.08-0.53 ± 0.10-0.01 ± 0.10
Week 8 (n=35, n=30, n=33, n=24, n=28)-0.33 ± 0.10-0.74 ± 0.10-0.78 ± 0.10-0.90 ± 0.12-0.00 ± 0.11
Statistical analysis
  • 0.1 Milligrams (mg) LY2189265 vs 0.5 Milligrams (mg) LY2189265 vs 1.0 Milligrams (mg) LY2189265 vs 1.5 Milligrams (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison at Week 4. A priori threshold for statistical significance was p\<0.05.)
  • 0.1 Milligrams (mg) LY2189265 vs 0.5 Milligrams (mg) LY2189265 vs 1.0 Milligrams (mg) LY2189265 vs 1.5 Milligrams (mg) LY2189265 · Mixed Models Analysis · p = 0.023 (Treatment comparison at Week 4. A priori threshold for statistical significance was p\<0.05.)
  • 0.1 Milligrams (mg) LY2189265 vs 0.5 Milligrams (mg) LY2189265 vs 1.0 Milligrams (mg) LY2189265 vs 1.5 Milligrams (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison at Week 8. A priori threshold for statistical significance was p\<0.05.)
  • 0.1 Milligrams (mg) LY2189265 vs 0.5 Milligrams (mg) LY2189265 vs 1.0 Milligrams (mg) LY2189265 vs 1.5 Milligrams (mg) LY2189265 · Mixed Models Analysis · p = <0.001 (Treatment comparison at Week 8. A priori threshold for statistical significance was P\<0.05.)
SecondaryChange From Baseline in Fasting Blood Glucose

Fasting blood glucose is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline fasting glucose as covariate.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in Fasting Blood Glucose
milligrams per deciliter (mg/dL)0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY2189265Placebo
Change From Baseline in Fasting Blood Glucose-11.59 ± 4.09-30.31 ± 4.26-33.73 ± 4.18-37.49 ± 4.78-3.78 ± 4.44
Statistical analysis
  • 0.1 Milligrams (mg) LY2189265 vs 0.5 Milligrams (mg) LY2189265 vs 1.0 Milligrams (mg) LY2189265 vs 1.5 Milligrams (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (A priori threshold for statistical significance was p\<0.05.)
  • 0.1 Milligrams (mg) LY2189265 vs 0.5 Milligrams (mg) LY2189265 vs 1.0 Milligrams (mg) LY2189265 vs 1.5 Milligrams (mg) LY2189265 · Mixed Models Analysis · p = <0.001 (A priori threshold for statistical significance was p\<0.05.)
  • 0.1 Milligrams (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.456 (An adjustment for multiplicity was performed when comparing the individual doses to placebo using a Dunnett's test.) · Mean difference (final values): -7.81
  • 0.5 Milligrams (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (An adjustment for multiplicity was performed when comparing the individual doses to placebo using a Dunnett's test.) · Mean difference (final values): -26.53
  • 1.0 Milligrams (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (An adjustment for multiplicity was performed when comparing the individual doses to placebo using a Dunnett's test.) · Mean difference (final values): -29.96
  • 1.5 Milligrams (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (An adjustment for multiplicity was performed when comparing the individual doses to placebo using a Dunnett's test.) · Mean difference (final values): -33.71
SecondaryPercentage of Participants Who Achieve Glycosylated Hemoglobin (HbA1c) <7% or ≤6.5%

Percentages of participants who achieved glycosylated hemoglobin (HbA1c) levels of \<7.0% or ≤6.5% were compared across treatment arms using the Cochran-Armitage trend test.

Time frame:
12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Glycosylated Hemoglobin (HbA1c) <7% or ≤6.5%
percentage of participants0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY2189265Placebo
HbA1c levels <7.0% (n=34, n=30, n=32, n=21, n=28)47.173.375.071.421.4
HbA1c levels ≤6.5% (n=34, n=30, n=32, n=21, n=28)14.753.350.052.47.1
Statistical analysis
  • 0.1 Milligrams (mg) LY2189265 vs 0.5 Milligrams (mg) LY2189265 vs 1.0 Milligrams (mg) LY2189265 vs 1.5 Milligrams (mg) LY2189265 vs Placebo · Cochran-Armitage trend test · p = <0.001 (Treatment comparison of glycosylated hemoglobin (HbA1c) levels \<7.0%.)The Cochran-Armitage trend test included the placebo arm.
  • 0.1 Milligrams (mg) LY2189265 vs 0.5 Milligrams (mg) LY2189265 vs 1.0 Milligrams (mg) LY2189265 vs 1.5 Milligrams (mg) LY2189265 vs Placebo · Cochran-Armitage trend test · p = <0.001 (Treatment comparison of glycosylated hemoglobin (HbA1c) levels ≤6.5%.)The Cochran-Armitage trend test included the placebo arm.
SecondaryChange From Baseline in Daily Mean Blood Glucose Values From the 7-point Self Monitored Blood Glucose (SMBG) Profiles

Change from baseline in mean daily blood glucose values were measured with a 7-point self-monitored blood glucose (SMBG) profile over a 24-hour period in the 7-day period prior to each visit. The 7-point SMBG profile consisted of preprandial blood glucose measures before the morning, midday, and evening meals; blood glucose measures 2 hours after the start of the morning, midday, and evening meals; and the fasting blood glucose obtained the following morning. Mean at 12 weeks was assessed in all treatment groups. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and as covariate.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in Daily Mean Blood Glucose Values From the 7-point Self Monitored Blood Glucose (SMBG) Profiles
milligrams per deciliter (mg/dL)0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY2189265Placebo
Change From Baseline in Daily Mean Blood Glucose Values From the 7-point Self Monitored Blood Glucose (SMBG) Profiles-15.77 ± 4.74-32.21 ± 4.88-42.46 ± 4.68-44.79 ± 5.46-6.12 ± 5.05
Statistical analysis
  • 0.1 Milligrams (mg) LY2189265 vs 0.5 Milligrams (mg) LY2189265 vs 1.0 Milligrams (mg) LY2189265 vs 1.5 Milligrams (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (A priori threshold for statistical significance was p\<0.05.)
  • 0.1 Milligrams (mg) LY2189265 vs 0.5 Milligrams (mg) LY2189265 vs 1.0 Milligrams (mg) LY2189265 vs 1.5 Milligrams (mg) LY2189265 · Mixed Models Analysis · p = <0.001 (A priori threshold for statistical significance was p\<0.05.)
  • 0.1 Milligrams (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.378 (An adjustment for multiplicity was performed when comparing the individual doses to placebo using a Dunnett's test.) · Mean difference (final values): -9.65
  • 0.5 Milligrams (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (An adjustment for multiplicity was performed when comparing the individual doses to placebo using a Dunnett's test.) · Mean difference (final values): -26.09
  • 1.0 Milligrams (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (An adjustment for multiplicity was performed when comparing the individual doses to placebo using a Dunnett's test.) · Mean difference (final values): -36.34
  • 1.5 Milligrams (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (An adjustment for multiplicity was performed when comparing the individual doses to placebo using a Dunnett's test.) · Mean difference (final values): -38.67
SecondaryChange From Baseline in Beta-cell Function (HOMA2-%B)

Change from baseline in beta (β)-cell function (HOMA2-%B) was assessed by using the homeostatic model assessment (HOMA) to quantify β-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta cell function (%B), as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. Least Squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline HOMA2-%B as covariate.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · percentage of HOMA2-%B
Change From Baseline in Beta-cell Function (HOMA2-%B)
percentage of HOMA2-%B0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY2189265Placebo
Change From Baseline in Beta-cell Function (HOMA2-%B)13.18 ± 6.7631.66 ± 7.0439.04 ± 7.6429.29 ± 8.11-2.06 ± 7.44
Statistical analysis
  • 0.1 Milligrams (mg) LY2189265 vs 0.5 Milligrams (mg) LY2189265 vs 1.0 Milligrams (mg) LY2189265 vs 1.5 Milligrams (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (A priori threshold for statistical significance was p\<0.05.)
  • 0.1 Milligrams (mg) LY2189265 vs 0.5 Milligrams (mg) LY2189265 vs 1.0 Milligrams (mg) LY2189265 vs 1.5 Milligrams (mg) LY2189265 · Mixed Models Analysis · p = 0.036 (A priori threshold for statistical significance was p\<0.05.)
SecondaryChange From Baseline in Insulin Sensitivity (HOMA2-%S)

Change from baseline in insulin sensitivity (HOMA2-%S) was assessed by using the homeostatic model assessment (HOMA) to quantify insulin sensitivity. HOMA2-%S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state insulin sensitivity (%S), as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. Least Squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline HOMA2-%S as covariate.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · percentage of HOMA2-%S
Change From Baseline in Insulin Sensitivity (HOMA2-%S)
percentage of HOMA2-%S0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY2189265Placebo
Change From Baseline in Insulin Sensitivity (HOMA2-%S)-2.41 ± 6.626.10 ± 6.92-4.80 ± 7.4412.98 ± 7.950.58 ± 7.34
Statistical analysis
  • 0.1 Milligrams (mg) LY2189265 vs 0.5 Milligrams (mg) LY2189265 vs 1.0 Milligrams (mg) LY2189265 vs 1.5 Milligrams (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.450 (A priori threshold for statistical significance was p\<0.05.)
  • 0.1 Milligrams (mg) LY2189265 vs 0.5 Milligrams (mg) LY2189265 vs 1.0 Milligrams (mg) LY2189265 vs 1.5 Milligrams (mg) LY2189265 · Mixed Models Analysis · p = 0.329 (A priori threshold for statistical significance was p\<0.05.)
SecondaryChange From Baseline in Electrocardiograms (ECGs) - Fridericia-corrected QT (QTcF) and PR Interval

The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. The PR segment begins at the endpoint of the P wave and ends at the onset of the QRS complex. Least Squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline measurement as covariate.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · millisecond (msec)
Change From Baseline in Electrocardiograms (ECGs) - Fridericia-corrected QT (QTcF) and PR Interval
millisecond (msec)0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY2189265Placebo
Fridericia-corrected QT (QTcF) Interval1.34 ± 2.09-1.18 ± 2.114.56 ± 2.01-0.63 ± 2.330.70 ± 2.19
PR Interval3.22 ± 2.204.57 ± 2.23-0.55 ± 2.152.83 ± 2.46-0.89 ± 2.33
SecondaryChange From Baseline in Electrocardiograms (ECGs) - Heart Rate

Least Squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline measurement as covariate.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · beats per minute (bpm)
Change From Baseline in Electrocardiograms (ECGs) - Heart Rate
beats per minute (bpm)0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY2189265Placebo
Change From Baseline in Electrocardiograms (ECGs) - Heart Rate1.38 ± 1.481.16 ± 1.511.88 ± 1.444.18 ± 1.670.67 ± 1.58
SecondaryChange From Baseline in Pulse Rate

Sitting pulse rate was measured. Least Squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline measurement as covariate.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · beats per minute (bpm)
Change From Baseline in Pulse Rate
beats per minute (bpm)0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY2189265Placebo
Change From Baseline in Pulse Rate0.19 ± 1.440.25 ± 1.491.02 ± 1.431.34 ± 1.651.29 ± 1.54
SecondaryChange From Baseline in Blood Pressure (BP)

Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change were calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline measurement as covariate.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline in Blood Pressure (BP)
millimeters of mercury (mmHg)0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY2189265Placebo
Sitting Systolic Blood Pressure-2.21 ± 2.040.51 ± 2.12-2.57 ± 2.021.88 ± 2.33-0.68 ± 2.18
Sitting Diastolic Blood Pressure-0.24 ± 1.210.59 ± 1.260.42 ± 1.201.56 ± 1.391.07 ± 1.30
SecondaryNumber of Participants With Self-reported Hypoglycemic Events

Hypoglycemic events were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined an event during which typical symptoms of hypoglycemia were accompanied by a blood glucose level of ≤3.9 millimoles per liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured blood glucose of ≤3.9 mmol/L), or nocturnal (defined as any hypoglycemic event that occurred between bedtime and breakfast with a measured blood glucose of ≤3.9 mmol/L). Participant reports of hypoglycemic events were collected at the beginning of each visit starting at Baseline. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 12 weeks
Reported as:
Number · participants
Number of Participants With Self-reported Hypoglycemic Events
participants0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY2189265Placebo
Documented Symptomatic02230
Asymptomatic10000
Severe00000
Nocturnal12120
SecondaryRate of Self-reported Hypoglycemic Events

Hypoglycemic events (HE) were classified as severe (defined as events requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined an event during which typical symptoms of hypoglycemia were accompanied by a blood glucose level of ≤3.9 millimoles per liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured blood glucose of ≤3.9 mmol/L), or nocturnal (defined as any HE that occurred between bedtime and breakfast with a measured blood glucose of ≤3.9 mmol/L). Participant reports of HE were collected at the beginning of each visit starting at Baseline and the annualized rate was reported. Least Squares (LS) means rates were adjusted for pre-study therapy, country, and baseline body mass index. A summary of AEs regardless of causality is located in the Reported AEs module. Some model-adjusted LS means are less than 0 and may be interpreted as very low rates.

Time frame:
Baseline through 12 weeks
Reported as:
Least squares mean · Events per participant per year
Rate of Self-reported Hypoglycemic Events
Events per participant per year0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY2189265Placebo
Documented Symptomatic Hypoglycemic Rate-0.08 ± 0.720.25 ± 0.731.68 ± 0.730.61 ± 0.79-0.09 ± 0.75
Asymptomatic Hypoglycemic Rate0.19 ± 0.10-0.01 ± 0.10-0.01 ± 0.100.02 ± 0.110.01 ± 0.11
Severe Hypoglycemic Rate0 ± 00 ± 00 ± 00 ± 00 ± 0
Nocturnal Hypoglycemic Rate0.20 ± 0.620.16 ± 0.641.21 ± 0.620.21 ± 0.71-0.08 ± 0.67
SecondaryTreatment Emergent Adverse Events

A treatment emergent adverse event is any untoward medical occurrence that either occurs or worsens at any time after the first injection of study drug following randomization and which does not necessarily have to have a causal relationship. The number of participants with one or more treatment emergent adverse event was reported. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 12 weeks
Reported as:
Number · participants
Treatment Emergent Adverse Events
participants0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY21892653.0 Milligrams (mg) LY2189265Placebo
Treatment Emergent Adverse Events21172018118
SecondaryChange From Baseline in Body Weight

Least Squares (LS) means was calculated using a mixed-effects model for repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline measurement as covariate.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · kilogram (kg)
Change From Baseline in Body Weight
kilogram (kg)0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY2189265Placebo
Change From Baseline in Body Weight-0.19 ± 0.42-0.34 ± 0.43-1.11 ± 0.42-1.49 ± 0.48-1.38 ± 0.45
Statistical analysis
  • 0.1 Milligrams (mg) LY2189265 vs 0.5 Milligrams (mg) LY2189265 vs 1.0 Milligrams (mg) LY2189265 vs 1.5 Milligrams (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.969 (A priori threshold for statistical significance was p\<0.05.)
  • 0.1 Milligrams (mg) LY2189265 vs 0.5 Milligrams (mg) LY2189265 vs 1.0 Milligrams (mg) LY2189265 vs 1.5 Milligrams (mg) LY2189265 · Mixed Models Analysis · p = 0.009 (A priori threshold for statistical significance was p\<0.05.)
  • 0.1 Milligrams (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.140 (An adjustment for multiplicity was performed when comparing the individual doses to placebo using a Dunnett's test.) · Mean difference (final values): 1.19
  • 0.5 Milligrams (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.247 (An adjustment for multiplicity was performed when comparing the individual doses to placebo using a Dunnett's test.) · Mean difference (final values): 1.04
  • 1.0 Milligrams (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.975 (An adjustment for multiplicity was performed when comparing the individual doses to placebo using a Dunnett's test.) · Mean difference (final values): 0.27
  • 1.5 Milligrams (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 1.00 (An adjustment for multiplicity was performed when comparing the individual doses to placebo using a Dunnett's test.) · Mean difference (final values): -0.11
SecondaryAntibody Production and Effects to LY2189265

LY2189265 anti-drug antibodies (ADA) were assessed at baseline, 4 and 12 weeks, and at the safety follow-up visit 4 weeks after study drug discontinuation (16 weeks). The number of participants with initial postbaseline detection of treatment emergent (defined as a 4-fold increase in the ADA titer from baseline) LY2189265 ADA at each time point were summarized.

Time frame:
Baseline, 4 weeks, 12 weeks, 16 weeks
Reported as:
Number · participants
Antibody Production and Effects to LY2189265
participants0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY2189265Placebo
Week 400100
Week 1200000
Week 1600000
SecondaryCollection and Evaluation of Plasma Levels (Pharmacokinetics [PK]) of LY2189265

The population mean estimates and standard deviations were calculated for pharmacokinetic parameters (area under the concentration time curve (AUC) from zero to 168 hours). Evaluable PK concentrations from the 4 week, 8 week, and 12 week timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.

Time frame:
4 weeks, 8 weeks, 12 weeks
Reported as:
Mean · nanograms*hour/milliliter (ng*h/mL)
Collection and Evaluation of Plasma Levels (Pharmacokinetics [PK]) of LY2189265
nanograms*hour/milliliter (ng*h/mL)0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY21892653.0 Milligrams (mg) LY2189265
Collection and Evaluation of Plasma Levels (Pharmacokinetics [PK]) of LY21892652294 ± 15036650 ± 435611671 ± 764516649 ± 1090531538 ± 20657

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.1 Milligrams (mg) LY2189265—0/35 (0%)20/35 (57.1%)
0.5 Milligrams (mg) LY2189265—1/34 (2.9%)16/34 (47.1%)
1.0 Milligrams (mg) LY2189265—1/34 (2.9%)17/34 (50%)
1.5 Milligrams (mg) LY2189265—1/29 (3.4%)15/29 (51.7%)
3.0 Milligrams (mg) LY2189265—0/3 (0%)1/3 (33.3%)
Placebo—1/32 (3.1%)15/32 (46.9%)
Most frequent serious events
Most frequent serious events
Event0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY21892653.0 Milligrams (mg) LY2189265Placebo
Abdominal distensionGastrointestinal disorders0/350/340/341/290/30/32
Abdominal painGastrointestinal disorders0/350/340/341/290/30/32
Pancreatitis haemorrhagicGastrointestinal disorders0/350/340/340/290/31/32
CholelithiasisHepatobiliary disorders0/350/340/340/290/31/32
Atrial flutterCardiac disorders0/350/341/340/290/30/32
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/351/340/340/290/30/32
Most frequent other events
Showing 10 of 58
Most frequent other events
Event0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY21892653.0 Milligrams (mg) LY2189265Placebo
PharyngitisInfections and infestations2/350/340/341/291/31/32
DyspepsiaGastrointestinal disorders2/350/341/344/290/30/32
NauseaGastrointestinal disorders4/350/344/342/290/33/32
HeadacheNervous system disorders1/350/344/342/290/30/32
ConstipationGastrointestinal disorders1/352/341/343/290/31/32
DiarrhoeaGastrointestinal disorders2/353/341/343/290/31/32
NasopharyngitisInfections and infestations0/352/342/343/290/32/32
Vulvovaginal mycotic infectionInfections and infestations0/240/180/180/160/31/14
Abdominal distensionGastrointestinal disorders2/351/340/342/290/30/32
VomitingGastrointestinal disorders1/350/340/342/290/32/32

Baseline characteristics

Participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY21892653.0 Milligrams (mg) LY2189265PlaceboTotal
Mean56.33 ± 9.1556.91 ± 9.0657.16 ± 8.7657.45 ± 7.8860.82 ± 7.1555.03 ± 9.3356.64 ± 8.78
Sex: Female, Male
Sex: Female, Male(Participants)0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY21892653.0 Milligrams (mg) LY2189265PlaceboTotal
Female2418181621492
Male1116161311875
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY21892653.0 Milligrams (mg) LY2189265PlaceboTotal
American Indian or Alaska Native1020003
Asian45540523
Black or African American1101115
Native Hawaiian or Other Pacific Islander0010001
White29282624225134
Multiple0000011
Region of Enrollment
Region of Enrollment(participants)0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY21892653.0 Milligrams (mg) LY2189265PlaceboTotal
United States1615131131775
Mexico55440523
Puerto Rico0122005
Spain2311018
Poland22550216
Croatia42230314
Russian Federation2120005
India45530421
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms/square meters (kg/m^2))0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY21892653.0 Milligrams (mg) LY2189265PlaceboTotal
Mean32.92 ± 4.7532.26 ± 5.3932.22 ± 4.5031.04 ± 4.2935.38 ± 3.9632.07 ± 5.2332.20 ± 4.83
Duration of Diabetes
Duration of Diabetes(years)0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY21892653.0 Milligrams (mg) LY2189265PlaceboTotal
Mean3.90 ± 3.193.72 ± 3.803.28 ± 2.544.62 ± 4.085.00 ± 3.043.91 ± 4.743.88 ± 3.68
Body Weight
Body Weight(kilogram (kg))0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY21892653.0 Milligrams (mg) LY2189265PlaceboTotal
Mean87.08 ± 17.2890.20 ± 21.3486.89 ± 16.9585.81 ± 18.63100.90 ± 25.5190.87 ± 18.9488.43 ± 18.68
Glycosylated Hemoglobin (HbA1c)
Glycosylated Hemoglobin (HbA1c)(percentage of glycosylated hemoglobin)0.1 Milligrams (mg) LY21892650.5 Milligrams (mg) LY21892651.0 Milligrams (mg) LY21892651.5 Milligrams (mg) LY21892653.0 Milligrams (mg) LY2189265PlaceboTotal
Mean7.13 ± 0.557.18 ± 0.607.28 ± 0.667.25 ± 0.437.63 ± 0.157.36 ± 0.637.24 ± 0.58
08

Study locations

46 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Concord, California 94520, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lancaster, California 93534, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mission Hills, California 91345, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Palm Springs, California 92262, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vincennes, Indiana 47591, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wichita, Kansas 67208, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bloomfield Hills, Michigan 48302, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Calabash, North Carolina 28467, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tabor City, North Carolina 28463, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beaver, Pennsylvania 15009, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    North Myrtle Beach, South Carolina 29582, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Menomonee Falls, Wisconsin 53051, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dubrovnik, 20000, Croatia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osijek, HR-31000, Croatia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Varazdin, HR-42000, Croatia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Zagreb, HR-10000, Croatia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aalborg, DK-9000, Denmark
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aarhus, 8000, Denmark
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Copenhagen, 2300, Denmark
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Frederiksberg, 2000, Denmark
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hillerod, Dk-3400, Denmark
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kobenhavn, 2400, Denmark
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bangalore, 560052, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bilaspur, 495006, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hyderabaad, 500001, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Indore, 452001, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kochin, 682026, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mumbai, 400 067, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New Delhi, 110 029, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexico City, 06700, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Monterrey, 64570, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bialystok, 15-950, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Szczecin, 71-252, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wroclaw, 503-349, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Carolina, 00983, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San German, 00685, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Arkhangelsk, 163045, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Moscow, 119881, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rostov-On-Don, 344022, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint Petersburg, 193257, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Alcira, 46600, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dos Hermanas, 41014, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lleida, 25198, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Malaga, 29010, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santa Cruz De Tenerife, 38320, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Torrevieja, 03186, Spain
09

References and documents

Publications

  • Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med. 2012 Oct;29(10):1260-7. doi: 10.1111/j.1464-5491.2012.03745.x. PubMed 22804250 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2014, 4 years 11 months after primary completion. A results delay was requested in Oct 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2008
First posted
Nov 14, 2008
Start
Dec 2008
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Results delay requested
Oct 25, 2010
Results first posted
Dec 10, 2014
Last update
Dec 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00791479
Responsible party
Sponsor
First posted
Nov 14, 2008
Start date
Dec 2008
Primary completion
Jan 2010
Completion
Jan 2010
Results posted
Dec 10, 2014
Last update
Dec 10, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
study chair · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion